Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $22.5 million.

  • Assembly Biosciences' Cash & Equivalents fell 20.80% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 20.80%. This contributed to the annual value of $38.3 million for FY2024, which is 93.26% up from last year.
  • Latest data reveals that Assembly Biosciences reported Cash & Equivalents of $22.5 million as of Q3 2025, which was down 6.13% from $24.0 million recorded in Q2 2025.
  • Assembly Biosciences' Cash & Equivalents' 5-year high stood at $78.3 million during Q1 2021, with a 5-year trough of $18.7 million in Q1 2024.
  • Over the past 3 years, Assembly Biosciences' median Cash & Equivalents value was $23.4 million (recorded in 2025), while the average stood at $26.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 62.15% in 2023, then surged by 93.26% in 2024.
  • Over the past 5 years, Assembly Biosciences' Cash & Equivalents (Quarterly) stood at $45.6 million in 2021, then rose by 14.88% to $52.4 million in 2022, then slumped by 62.15% to $19.8 million in 2023, then surged by 93.26% to $38.3 million in 2024, then fell by 20.80% to $22.5 million in 2025.
  • Its Cash & Equivalents stands at $22.5 million for Q3 2025, versus $24.0 million for Q2 2025 and $23.4 million for Q1 2025.